InnoCan Pharma ( ($TSE:INNO) ) has shared an update. Innocan Pharma Corporation plans to list its common shares on the NYSE American around ...

Management projected 2025 Portfolio Receipts between $2.9 billion and $3.05 billion, reflecting 4%-9% growth. This guidance excludes the impact of potential future royalty acquisitions. Operating ...

On Wednesday, JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while ...

CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with petrelintide and ...

The average one-year price target for Athira Pharma (NasdaqCM:ATHA) has been revised to $4.08 / share. This is an increase of 700.00% from the prior estimate of $0.51 dated September 10, 2025. The ...

Target will pay $3 million to resolve allegations that the company automatically refilled Medicaid recipients’ prescriptions without explicit request in Massachusetts. The allegations violate the ...

The average one-year price target for Medicus Pharma (NasdaqCM:MDCX) has been revised to $22.78 / share. This is an increase of 13.56% from the prior estimate of $20.06 dated September 27, 2025. The ...

Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $180 from $175 and keeps an Equal Weight rating on the shares after updating the firm’s model for recently reported Q4 ...

Other factors driving interest in payer services are first-time investors and experienced ones seeking to increase their ...

Pharmaceutical companies are spending more on marketing than ever before, driven by factors including the aging of the population, the increased prevalence of chronic disease and the growing ...